We're excited to share an interview with Dr. Mark Traill, who is the owner of MammoBot LLC. Mammobot is a cloud-based startup that offers a double reading of screening 2D or 3D mammograms using artificial intelligence algorithms. Clients can upload mammogram studies that become part of the investigational protocol prior to pending FDA approval of the algorithm. Review of the mammogram study by AI algorithms has the potential of detecting early breast cancer that was missed on the initial human review of images. Ambra Health: When did Mammobot begin?

TeraRecon, Ambra Health and EnvoyAI announced a new collaboration March 6 to create an artificial intelligence (AI)-enhanced image exchange workflow for healthcare providers, according to a recent press release. "Through our partnerships with Ambra Health and TeraRecon, our technology can reach remote, single physician practices while also meeting the most demanding clinical needs of the largest integrated health systems," said Jake Taylor, CTO of EnvoyAI. The new partnership will allow providers to implement AI through an Ambra image exchange workflow while having full access to an AI algorithm portfolio available on the EnvoyAI Exchange, ultimately leveraging healthcare provdiers' current PACS and the full range of TeraRecon viewers, according to the press release. "This interoperability partnership gives healthcare providers in the Ambra network access to bleeding edge AI technology for advanced image visualization, providing the very latest technological innovations to continually improve patient outcomes and care," said Andrew Duckworth, vice president of business development for Ambra Health, in a prepared statement. The new AI workflow will be on display until Thursday, March 8. at HIMSS18 annual meeting in Las Vegas.